Bildkälla: Stockfoto

Faron Pharmaceuticals: Positive FDA Feedback on Bexmarilimab - Redeye

Redeye is encouraged to learn that Faron has received positive FDA feedback and recommendations for the future development of lead candidate Bexmarilimab as a monotherapy in multiple solid tumors. We believe this is a great validation of Faron’s development plan for Bexmarilimab and the robust clinical data package generated through the MATINS trial.

Redeye is encouraged to learn that Faron has received positive FDA feedback and recommendations for the future development of lead candidate Bexmarilimab as a monotherapy in multiple solid tumors. We believe this is a great validation of Faron’s development plan for Bexmarilimab and the robust clinical data package generated through the MATINS trial.
Börsvärldens nyhetsbrev
ANNONSER